

Special Issue

Current Challenge and Future Advances for Lung Cancer: Genetics, Instrumental Diagnosis and Treatment

Message from the Guest Editor

Dear colleagues, This Special Issue will include data on potential new diagnostic and therapeutic discoveries that aim to improve the prognosis of lung cancer patients. We welcome basic translational and clinical research papers, studies on cancer biomarkers, professional opinions, and reviews in the broad field of lung cancer diagnosis and therapy in the following categories: Lung cancer diagnosis. Lung cancer metastases (with an emphasis on CNS metastases). Lung cancer surgery. Lung cancer radiotherapy. Lung cancer chemotherapy. Lung cancer target therapies. Lung cancer immunotherapy. Elderly populations with lung cancer. Side effects of lung cancer therapies. Surrogate biomarkers in lung cancer. Preclinical and translational research in lung cancer. Thanks a lot. Dahlia Wang

Guest Editor

Dr. Giovanni Vicidomini

Thoracic Surgery Unit, University of Campania Luigi Vanvitelli, I-80138 Naples, Italy

Deadline for manuscript submissions

closed (10 November 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/109279

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)